Drug Profile
AZD 0424
Alternative Names: AZD0424Latest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; Cancer Research UK
- Class Antineoplastics; Small molecules
- Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Src-Family kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy) in United Kingdom (PO)
- 28 Sep 2022 No recent reports of development identified for phase-I development in Solid-tumours(Monotherapy) in United Kingdom (PO)
- 15 Sep 2020 AZD 0424 is still in phase I trials for Solid tumours in United Kingdom (PO) (Cancer Research UK pipeline, September 2020)